Copd Associated With Chronic Bronchitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for copd associated with chronic bronchitis. 186 active patents protecting 2 drugs from 2+ originators. First major cliff: 2037. Daily refresh.

2
Approved drugs
186
Active US patents
60/100
Avg vulnerability
$69M
Annual revenue covered

Originators in Copd Associated With Chronic Bronchitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Arcutis 68 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating copd associated with chronic bronchitis. Each bar = one year. Y-axis scaled to peak year (65 patents).

2
26
29
31
8
34
15
35
8
36
65
37
21
39
28
40
7
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Daliresp
ROFLUMILAST
 Arcutis 68 62 — 2037-06-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
9907788 Daliresp method of use 75 2037-06-07
11992480 Daliresp method of use 75 2037-06-07
12310956 Daliresp method of use 75 2037-06-07
11992480 Daliresp method of use 75 2037-06-07
11992480 Daliresp method of use 75 2037-06-07
11992480 Daliresp method of use 75 2037-06-07
12005051 Daliresp method of use 75 2037-06-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14

Related